Short traders are more bearish on shares of TESARO, Inc. if you evaluate the change in short interest. The company had a rise in short interest of 5.22% as of August 31, 2017 from the last reporting period. Short shares increased from 9,208,710 to 9,689,042 over that period. With short interest at 9,689,042 and short average daily volume at 1,022,688, the short-interest ratio is 9.0 and the short interest percentage is 0.18% as of August 31.
Here is a rundown on some insider market activity for TESARO, Inc. (NASDAQ:TSRO). VP Edward C. English let go of 10,862 shares at an average price of $135.35 on Wed the 6th. The VP now owns $53,599 of the stock as reported to the SEC. SVP & GM, International Orlando Oliveira sold 71 shares at an average price of $132.66 on Tue the 5th. That brings Oliveira’s holdings to $869,586 per an SEC filing yesterday.
Grant C. Bogle, Sr. VP, Chief Commercial Ofc. sold $1,912,545 worth of shares at an average price of $135.00 on September 1st. Bogle now owns $39,555 of stock as recorded in a recent Form 4 SEC filing.
A few notable investment firms have updated their holdings. As of the end of the quarter Janus Capital Management LLC had disposed of a total of 129,833 shares trimming its holdings by 17.0%. The value of the investment in TESARO, Inc. decreased from $102,659,000 to $97,477,000 a change of $5,182,000 for the reporting period. As of quarter end Rock Springs Capital Management Lp had bought 15,600 shares growing its stake by 3.3%. The value of the investment in TSRO went from $73,073,000 to $68,601,000 a change of 6.1% since the last quarter.
As of quarter end Venbio Select Advisor LLC had disposed of a total of 11,420 shares trimming its position 2.8%. The value of the total investment in TESARO, Inc. went from $63,367,000 to $56,000,000 decreasing 11.6% quarter over quarter. As of quarter end Jane Street Group, LLC had bought 25,883 shares growing its stake by 6,207.0%. The value of the company’s investment in TESARO, Inc. increased from $64,000 to $3,678,000 a change of $3,614,000 quarter to quarter.
Equity analyst RBC Capital initiated coverage on the stock with a rating of “Sector Perform”. On August 18 Credit Suisse left the stock rating at “Outperform” but moved up the price target from $122.00 to $190.00.
On August 17, 2017 Evercore ISI Group added the stock to its research portfolio setting a rating of “In-Line”.
The company is now up by 1.95%% since yesterday’s close of 118.74. Company shares last traded at $121.05 which is a tad above $121.03, the 50 day moving average and a great deal lower than the 200 day moving average of $138.94. The 50 day moving average was up $0.02 whereas the 200 day average was down by -12.88%.
In the last earnings report the EPS was $-9.95 and is estimated to be $-8.67 for the current year with 54,180,000 shares outstanding. Next quarter’s EPS is estimated at $-2.26 with next year’s EPS anticipated to be $-5.46.
TESARO, Inc., launched on March 26, 2010, is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. The Company is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform..